Navigation Links
Azithromycin Doesn't Always Help Lungs in Cystic Fibrosis Patients
Date:5/4/2010

Antibiotic helped some with respiratory disease, but more study needed

TUESDAY, May 4 (HealthDay News) -- Treatment with the antibiotic azithromycin doesn't improve the lung function of children and teens with cystic fibrosis, U.S. researchers report.

"A vicious cycle of infection and inflammation causes progressive lung destruction and premature death in patients with cystic fibrosis [CF]. Treatment strategies have therefore included both antimicrobial and anti-inflammatory agents," Dr. Lisa Saiman, of Columbia University in New York City, said in a news release.

Over the past decade, studies have suggested that azithromycin, an antibiotic with both antimicrobial and anti-inflammatory activity, benefits CF patients.

Azithromycin is recommended as therapy for CF patients with chronic infection with the bacteria Pseudomonas aeruginosa, but there has not been enough evidence to support the benefit of azithromycin in other patients with CF, the researchers wrote.

This study, which investigated the possible benefits of expanding the antibiotic therapy to CF patients without the pathogen, included 260 children and teens with CF who were not infected with P. aeruginosa. They were randomly selected to receive either azithromycin or a placebo. After 24 weeks of treatment, there was no difference in lung function between the two groups.

However, researchers found that when compared with the placebo group, the azithromycin group had 50 percent fewer pulmonary exacerbations and 27 percent fewer patients who had to begin new oral antibiotics (other than azithromycin). On average, they also showed a 1.3-pound weight gain and a 0.34-unit increase in body-mass index (important because CF patients often need to gain weight). There were no differences in treatment groups in the use of intravenous or inhaled antibiotics or hospitalizations, Saiman and colleagues added.

They also found that patients who took the antibiotic had less cough and less productive cough than those in the placebo group.

"Further studies of azithromycin are warranted to further investigate its potential use" in CF patients not infected with P. aeruginosa, the researchers concluded.

The study appears in the May 5 issue of the Journal of the American Medical Association.

More information

The U.S. National Library of Medicine has more about cystic fibrosis.



-- Robert Preidt



SOURCE:Journal of the American Medical Association, news release, May 5, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. New studies on surgical options in inherited breast cancer show drastic treatment is not always best
2. SAN SnapShot Backup for VMWare - Does Your Backup Always Completes In Seconds, Is 1000x Faster and Costs 90% Less?
3. Rotary Clubs Always Pumped for World Water Day
4. Patient and doctor expectations from joint replacement surgeries not always aligned
5. Its Not Always Women and Children First
6. Liberal Thinking: It, and It Alone, Has Always Been the Force Behind Positive Social Changes in America
7. Methadone and Other Opioids Not Always Equivalent, Conversion Can Be Lethal
8. Top-rated hospitals dont always have superior outcomes
9. Research findings underscore needed action to safeguard lungs of young cancer survivors
10. New technique reduces tobacco smoke damage to lungs in mice
11. Discovery in Lungs May Lead to Treatment for Respiratory Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... 06, 2016 , ... RowdMap, Inc. co-founder, Joshua Rosenthal, PhD, ... Principal Deputy Administrator at Centers for Medicare and Medicaid Services (CMS); Ali Khan, ... Medical Officer at Health Care Service Corporation (Blue Cross and Blue Shield of ...
(Date:5/5/2016)... ... May 05, 2016 , ... Pivot ... the industry’s gold standard KLAS Performance Report, Epic Consulting 2016 - ... organizations that specialize in consulting services for electronic health record (EHR) solutions from ...
(Date:5/5/2016)... ... 2016 , ... The U.S. Food and Drug Administration today ... submit their products through an arduous federal approval process. The rules, which treat ... market since February 15, 2007. That would essentially ban 99 percent of all ...
(Date:5/5/2016)... , ... May 05, 2016 , ... TLC Laser Eye ... Diego, California. The laser eye center will now be called “Gordon Schanzlin New Vision ... staff will remain at the full-service facility to ensure that patients continue to receive ...
(Date:5/5/2016)... ... May 05, 2016 , ... Phycologia ... A (UV-A) for photosynthesis, researchers Juntian Xu and Kunshan Gao tested the magnitude ... pair observed that when photosynthetically active radiation (i.e. the white light in our ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... According to market research "Global Computed ... to 2022 - Industry Insights by Slice Type (High, Mid ... by P&S Market Research, the global computed tomography market ... is expected to grow at a CAGR of 5.0% during ... is expected to witness the faster growth, CAGR of 5.3%, ...
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Acute Ischemic Stroke Market ... to their offering.       (Logo: ... Global Acute Ischemic Stroke Market and Competitive ... Acute Ischemic Stroke pipeline products, Acute Ischemic ...
(Date:5/3/2016)... , May 3, 2016 BioNovus Innovations ... Institute for Advancing Medical Innovation (IAMI) today announced ... drugs, diagnostics and medical devices. An ... with rights to license, develop and commercialize medical ... "This partnership represents a significant advance ...
Breaking Medicine Technology: